KMDA Kamada Ltd.

5.16
-0.13  -2%
Previous Close 5.29
Open 5.23
Price To Book 1.68
Market Cap 207,922,602
Shares 40,295,078
Volume 10,885
Short Ratio
Av. Daily Volume 25,223
Stock charts supplied by TradingView

NewsSee all news

  1. Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference

    REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a

  2. Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda

    Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due YE 2019.
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
Approval announced August 25, 2017.
KamRAB
Prophylaxis of rabies disease
Phase 3 (Europe) trial planned for 2H 2019.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2 data released November 3, 2017. No significant treatment effect noted overall.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2 interim data due YE 2019.
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)

Latest News

  1. Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference

    REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a

  2. Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda

    Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada